ANXA11 mutations lead to intracellular Ca2+ homeostasis dysregulation and abnormal protein aggregation, which may lead to MN death, and based on these Nahm et al. (2020) suggest that a multi-target therapeutic strategy may be an ideal integrative approach for more effective ALS management. The gene discussed is ANXA11; the disease is amyotrophic lateral sclerosis.